Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Plx Pharma Inc (PLXP)

Plx Pharma Inc (PLXP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,927
  • Shares Outstanding, K 9,156
  • Annual Sales, $ 570 K
  • Annual Income, $ -20,500 K
  • 60-Month Beta 4.30
  • Price/Sales 49.02
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.42
  • Number of Estimates 1
  • High Estimate -0.42
  • Low Estimate -0.42
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.72 +12.59%
on 07/16/20
3.28 -6.70%
on 07/06/20
-0.05 (-1.59%)
since 07/02/20
3-Month
2.36 +29.66%
on 05/11/20
4.84 -36.78%
on 05/26/20
+0.28 (+10.07%)
since 05/01/20
52-Week
1.80 +70.00%
on 03/25/20
6.53 -53.17%
on 08/14/19
-2.94 (-49.00%)
since 08/02/19

Most Recent Stories

More News
PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.06 (+0.33%)
PLx Pharma Inc. Reports First Quarter 2020 Results

-- Company to begin bioequivalence study of VAZALORE 325 mg dose --

PLXP : 3.06 (+0.33%)
PLx Pharma Inc. to Discuss 2020 First Quarter Financial Results on May 15, 2020 Conference Call

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery system to...

PLXP : 3.06 (+0.33%)
PLx Pharma Inc. Reports Fourth Quarter 2019 Results and Provides Regulatory Update on VAZALORE

-- Planning a Bioequivalence Study to Support VAZALORE 325 mg sNDA --

PLXP : 3.06 (+0.33%)
PLx Pharma Inc. to Discuss 2019 Fourth Quarter and Full Year Financial Results on March 13, 2020 Conference Call

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard(TM) delivery...

PLXP : 3.06 (+0.33%)
PLx Pharma Inc. Presents Original Abstract and Simultaneous Publication of its Novel, Liquid-Filled Capsule Aspirin Formulation at the 2020 International Stroke Conference

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard(TM) delivery...

PLXP : 3.06 (+0.33%)
PLx Pharma Inc. to Present at Biotech Showcase 2020

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.06 (+0.33%)
PLx Pharma Inc. Provides Regulatory Update on VAZALORE

-- PLx Aligning with the FDA on Data Requirements for VAZALORE

PLXP : 3.06 (+0.33%)
PLx Pharma Inc. Reports Third Quarter 2019 Results

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.06 (+0.33%)
PLx Pharma Inc. to Discuss 2019 Third Quarter Financial Results on November 8, 2019 Conference Call

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.06 (+0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade PLXP with:

Business Summary

PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe and effective aspirin products. PLx Pharma Inc., formerly known as Dipexium Pharmaceuticals Inc., is based in NEW YORK, United States....

See More

Key Turning Points

2nd Resistance Point 3.25
1st Resistance Point 3.15
Last Price 3.06
1st Support Level 2.95
2nd Support Level 2.85

See More

52-Week High 6.53
Fibonacci 61.8% 4.73
Fibonacci 50% 4.17
Fibonacci 38.2% 3.61
Last Price 3.06
52-Week Low 1.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar